IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS
The present invention provides IP4-4,6 substituted derivatives, their methods of synthesis and their uses. In some aspects, the IP4-4,6 derivative is a compound of formula I wherein R 1 , R 3 , R 7 , and R 11 are OPO 3 2− , and R 5 and R 9 are selected from the group consisting of —O(Alkyl) n X, —O(Alkyl) y Cy(Alkyl 2 ) y -Z, —O(Alkyl) y A(Alkyl) y -Z′, and their thiophosphate analogs. Also provided are methods, pharmaceutical compositions and formulations, methods of use, articles of manufacture, and kits for the treatment of diseases and conditions such as pathological crystallization-related diseases and conditions.
1 . A compound of general formula I:
a pharmaceutically acceptable salt thereof, or a combination thereof, wherein
(i) R 1 , R 3 , R 7 , and R 11 independently represent OPO 3 2− ; R 5 and R 9 are substituent groups each one corresponding to the formula —O(Alkyl) n X, wherein n is an integer between 1 and 20, wherein the terminal group X is selected from the group consisting of —H, —OR, —NRR′, —COOR, —CONRR′, —NHCOR, —NHCOOR, —OCONR, —NHSO 2 R, —NHCONRR′, halogen, —CF 3 , carbocycle (saturated or unsaturated), and heterocycle (saturated or unsaturated), and wherein R and R′ are H or an alkyl group;
(ii) R 1 , R 3 , R 7 , and R 11 independently represent OPO 3 2− ; R 5 and R 9 are substituent groups each one corresponding to the formula —O(Alkyl) y Cy(Alkyl) y -Z, wherein y is an integer between 0 and 10, wherein Cy is a cyclic linker, wherein the terminal group Z is selected from the group consisting of alkyl, —COR, —OR, —NRR′, —COOR, —CONRR′, —NHCOR, —NHCOOR, —OCONR —NHSO 2 R, —NHCONRR′, halogen, and —CF 3 , and wherein R and R′ are H or an alkyl group;
(iii) R 1 , R 3 , R 7 , and R 11 independently represent OPO 3 2− ; R 5 and R 9 are substituent groups each one corresponding to the formula —O(Alkyl) y A(Alkyl) y -Z′, wherein y is an integer between 0 and 10, wherein A is a linker selected from the group consisting of —CONR—, —NHCOO—, —NHSO 2 , —NHCONR—, —NHCO—, and —OCONR, wherein the terminal group Z′ is selected from the group consisting of —OR, —NRR′, —COOR, —CONRR′, —NHCOR, —NHCOOR, —OCONR, —NHSO 2 R, —NHCONRR′, carbocycle (saturated or unsaturated), heterocycle (saturated or unsaturated), and wherein R and R′ are H or an alkyl group; and
(iv) the compound of formula I is an analog of (i), (ii) or (iii) wherein at least one of R 1 , R 3 , R 7 or R 1 is thiophosphate (—OPSO 2 2− ).
2 . The compound according to claim 1 , wherein R 5 and R 9 are identical substituent groups.
3 . The compound according to any one of claims 1 to 2 , wherein the pharmaceutically acceptable salt is a sodium salt.
4 . The compound according to claim 3 , wherein the sodium salt is a tetrasodium salt, pentasodium salt, hexasodium salt, heptasodium salt, octasodium salt, nonasodium salt or decasodium salt.
5 . The compound according to claim 3 , wherein the sodium salt is a tetrasodium salt, pentasodium salt, hexasodium salt, heptasodium salt or octasodium salt.
6 . The compound according to claim 3 , wherein the sodium salt is a hexasodium salt, octasodium salt, nonasodium salt or decasodium salt.
7 . The compound according to claim 3 , wherein the sodium salt is an octasodium salt or nonasodium salt.
8 . The compound according to any one of claims 1 to 7 , wherein the compound is selected from the group consisting of Compound 1 to Compound 53, and any combination thereof.
9 . A pharmaceutical composition comprising a compound according to any one of claims 1 to 8 and at least one pharmaceutically acceptable excipient.
10 . A method to inhibit the formation or growth of a calcium salt/crystal in a subject in need thereof comprising administering to the subject an effective amount of a compound of formula I according to any one of claims 1 to 8 , or a pharmaceutical composition according to claim 9 .
11 . A method to inhibit the formation or growth of a calcium salt/crystal according to claim 10 , wherein calcium salt/crystal is a calcium phosphate.
12 . A method to inhibit the formation or growth of a calcium salt/crystal according to claim 11 , wherein the calcium phosphate is hydroxyapatite.
13 . A method to treat or prevent a disease or condition associated with pathological crystallization in a subject in need thereof comprising administering to the subject an effective amount of a compound of formula I according to any one of claims 1 to 8 , or a pharmaceutical composition according to claim 9 .
14 . A method to inhibit the progression of a crystallization process in a subject in need thereof comprising administering to the subject an effective amount of a compound of formula I according to any one of claims 1 to 8 , or a pharmaceutical composition according to claim 9 .
15 . A method to recover or increase blood perfusion in a subject in need thereof comprising administering to the subject an effective amount of a compound of formula I according to any one of claims 1 to 8 , or a pharmaceutical composition according to claim 9 .
16 . The methods according to any one of claims 10 to 15 , wherein the subject is human.
17 . The methods according to any one of claims 10 to 16 , wherein the administration is topical, enteral or parenteral.
18 . The methods according to claim 17 , wherein the parenteral administration is intravenous or subcutaneous.
19 . A compound selected from the group consisting of the compounds listed in Table 1.
20 . A kit or article of manufacture comprising at least one compound according to any one of claims 1 to 8 , a pharmaceutical composition according to claim 9 , or a compound according to claim 19 .
21 . A process of making a compound of formula I according to any one of claims 1 to 8 comprising the use of at least one compound according to claim 19 .